dc.contributor.author | Siersbæk, R | |
dc.contributor.author | Scabia, V | |
dc.contributor.author | Nagarajan, S | |
dc.contributor.author | Chernukhin, I | |
dc.contributor.author | Papachristou, EK | |
dc.contributor.author | Broome, R | |
dc.contributor.author | Johnston, SJ | |
dc.contributor.author | Joosten, SEP | |
dc.contributor.author | Green, AR | |
dc.contributor.author | Kumar, S | |
dc.contributor.author | Jones, J | |
dc.contributor.author | Omarjee, S | |
dc.contributor.author | Alvarez-Fernandez, R | |
dc.contributor.author | Glont, S | |
dc.contributor.author | Aitken, SJ | |
dc.contributor.author | Kishore, K | |
dc.contributor.author | Cheeseman, D | |
dc.contributor.author | Rakha, EA | |
dc.contributor.author | D'Santos, C | |
dc.contributor.author | Zwart, W | |
dc.contributor.author | Russell, A | |
dc.contributor.author | Brisken, C | |
dc.contributor.author | Carroll, JS | |
dc.date.accessioned | 2021-01-11T11:49:01Z | |
dc.date.issued | 2020-09-14 | |
dc.identifier.citation | Cancer cell, 2020, 38 (3), pp. 412 - 423.e9 | |
dc.identifier.issn | 1535-6108 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4273 | |
dc.identifier.eissn | 1878-3686 | |
dc.identifier.doi | 10.1016/j.ccell.2020.06.007 | |
dc.description.abstract | The cytokine interleukin-6 (IL6) and its downstream effector STAT3 constitute a key oncogenic pathway, which has been thought to be functionally connected to estrogen receptor α (ER) in breast cancer. We demonstrate that IL6/STAT3 signaling drives metastasis in ER+ breast cancer independent of ER. STAT3 hijacks a subset of ER enhancers to drive a distinct transcriptional program. Although these enhancers are shared by both STAT3 and ER, IL6/STAT3 activity is refractory to standard ER-targeted therapies. Instead, inhibition of STAT3 activity using the JAK inhibitor ruxolitinib decreases breast cancer invasion in vivo. Therefore, IL6/STAT3 and ER oncogenic pathways are functionally decoupled, highlighting the potential of IL6/STAT3-targeted therapies in ER+ breast cancer. | |
dc.format | Print-Electronic | |
dc.format.extent | 412 - 423.e9 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | CELL PRESS | |
dc.rights.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
dc.title | IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2020-06-12 | |
rioxxterms.versionofrecord | 10.1016/j.ccell.2020.06.007 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
rioxxterms.licenseref.startdate | 2020-09 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Cancer cell | |
pubs.issue | 3 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrine control mechanisms | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrine control mechanisms | |
pubs.publication-status | Published | |
pubs.volume | 38 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Endocrine control mechanisms | |
dc.contributor.icrauthor | Brisken, Cathrin | |